Legislation known as the BIOSECURE Act, aimed at limiting U.S. pharmaceutical and biotechnology companies’ dealings with Chinese biotech firms such as WuXi AppTec and WuXi Biologics, is under consideration in Congress. The bill has bipartisan support and could be attached to either a crucial defense budget or government funding legislation. The potential impact of this act includes increased costs for drugmakers, as the biopharma industry heavily relies on these Chinese companies for contract manufacturing and essential services. The bill is seen as a signal of toughness on China, with the outcome depending on its passage in December.
Source link
BIOSECURE Act on Chinese biotechs is harder to pass next year
